Shionogi agreed to pay $2 billion upfront to acquire IntraBio, adding a marketed treatment for two inherited conditions—an expansion of its rare-disease strategy. The purchase underscores how big pharma is prioritizing commercial-stage assets in orphan indications as well as pipeline expansion via platform-like disease franchises.